Analysts forecast that NuVasive, Inc. (NASDAQ:NUVA) will announce earnings per share of $0.45 for the current fiscal quarter, according to Zacks. Six analysts have made estimates for NuVasive’s earnings, with the highest EPS estimate coming in at $0.49 and the lowest estimate coming in at $0.41. NuVasive reported earnings per share of $0.38 during the same quarter last year, which would suggest a positive year over year growth rate of 18.4%. The company is scheduled to issue its next quarterly earnings report on Tuesday, April 24th.
On average, analysts expect that NuVasive will report full year earnings of $2.46 per share for the current year, with EPS estimates ranging from $2.44 to $2.48. For the next financial year, analysts expect that the business will report earnings of $2.81 per share, with EPS estimates ranging from $2.60 to $2.87. Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that cover NuVasive.
NuVasive (NASDAQ:NUVA) last released its quarterly earnings results on Monday, February 26th. The medical device company reported $0.56 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.56. NuVasive had a return on equity of 13.40% and a net margin of 8.06%. The company had revenue of $271.70 million during the quarter, compared to analysts’ expectations of $272.11 million. During the same period in the previous year, the firm posted $0.53 earnings per share. The business’s revenue for the quarter was up .2% compared to the same quarter last year.
Shares of NASDAQ NUVA traded down $0.50 during trading on Friday, reaching $54.42. The company had a trading volume of 704,522 shares, compared to its average volume of 919,681. NuVasive has a twelve month low of $44.62 and a twelve month high of $81.68. The stock has a market cap of $2,772.53, a price-to-earnings ratio of 28.49, a price-to-earnings-growth ratio of 1.45 and a beta of 0.38. The company has a quick ratio of 1.94, a current ratio of 3.48 and a debt-to-equity ratio of 0.73.
In other NuVasive news, CEO Gregory T. Lucier bought 6,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 6th. The stock was purchased at an average cost of $50.30 per share, for a total transaction of $301,800.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.20% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in NUVA. Westside Investment Management Inc. increased its stake in NuVasive by 76.0% in the fourth quarter. Westside Investment Management Inc. now owns 2,640 shares of the medical device company’s stock valued at $147,000 after purchasing an additional 1,140 shares during the last quarter. Zions Bancorporation acquired a new stake in NuVasive during the third quarter worth about $160,000. Baird Financial Group Inc. acquired a new stake in NuVasive during the fourth quarter worth about $205,000. Xact Kapitalforvaltning AB acquired a new stake in NuVasive during the fourth quarter worth about $293,000. Finally, Meadow Creek Investment Management LLC increased its stake in NuVasive by 22.0% during the fourth quarter. Meadow Creek Investment Management LLC now owns 7,344 shares of the medical device company’s stock worth $429,000 after acquiring an additional 1,326 shares during the last quarter.
TRADEMARK VIOLATION WARNING: This report was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3336458/0-45-eps-expected-for-nuvasive-inc-nuva-this-quarter.html.
NuVasive Company Profile
NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.